Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.690
+0.030 (1.81%)
Jul 17, 2026, 3:32 PM EDT - Market open
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
72.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 55.18K | -84.93K | -60.62% |
| Dec 31, 2022 | 140.11K | -24.89K | -15.08% |
| Dec 31, 2021 | 164.99K | 136.11K | 471.29% |
| Dec 31, 2020 | 28.88K | -12.42K | -30.07% |
| Dec 31, 2019 | 41.30K | 20.69K | 100.40% |
| Dec 31, 2018 | 20.61K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGANX News
- 1 day ago - Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update - GlobeNewsWire
- 17 days ago - Gain Therapeutics receives FDA clearance of GT-02287 IND application - TheFly
- 17 days ago - Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease - GlobeNewsWire
- 4 weeks ago - Gain Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 5 weeks ago - Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - GlobeNewsWire
- 5 weeks ago - Gain Therapeutics Slides: Corporate presentation - Filings
- 7 weeks ago - Gain Therapeutics presents data from Phase 1b study of GT-02287 - TheFly
- 7 weeks ago - Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 - GlobeNewsWire